Brainstorm Cell Therapeutics Inc

0
STU:GHD (USA)  
€ 2.98 (0%) Oct 28
At Loss
Market Cap:
€ 9.99M ($ 10.81M)
Enterprise V:
€ 7.67M ($ 8.30M)
Volume:
-
Avg Vol (2M):
-
Trade In:

Business Description

Description
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Name Current Vs Industry Vs History
Cash-To-Debt 3.61
Equity-to-Asset -0.62
Debt-to-Equity -0.27
Debt-to-EBITDA -0.06
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 21.15
9-Day RSI 27.54
14-Day RSI 32.38
6-1 Month Momentum % -57.58
12-1 Month Momentum % 42.86

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.5
Quick Ratio 0.5
Cash Ratio 0.45

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -19.8
Shareholder Yield % -139.56
Name Current Vs Industry Vs History
ROA % -258.35
ROIC % -364.61
3-Year ROIIC % -151.62
ROC (Joel Greenblatt) % -570.11

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -0.51
EV-to-Forward-EBIT -0.56
EV-to-EBITDA -0.52
EV-to-Forward-EBITDA -0.58
EV-to-FCF -0.57
Earnings Yield (Greenblatt) % -196.08
FCF Yield % -133.82

Financials (Next Earnings Date:2024-11-14 Est.)

STU:GHD's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Brainstorm Cell Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -3.182
Beta 0.35
Volatility % 118.61
14-Day RSI 32.38
14-Day ATR (€) 0.047128
20-Day SMA (€) 2.979
12-1 Month Momentum % 42.86
52-Week Range (€) 2.009999 - 13.199999
Shares Outstanding (Mil) 5.32

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Brainstorm Cell Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Brainstorm Cell Therapeutics Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Brainstorm Cell Therapeutics Inc Frequently Asked Questions

What is Brainstorm Cell Therapeutics Inc(STU:GHD)'s stock price today?
The current price of STU:GHD is €2.98. The 52 week high of STU:GHD is €13.20 and 52 week low is €2.01.
When is next earnings date of Brainstorm Cell Therapeutics Inc(STU:GHD)?
The next earnings date of Brainstorm Cell Therapeutics Inc(STU:GHD) is 2024-11-14 Est..
Does Brainstorm Cell Therapeutics Inc(STU:GHD) pay dividends? If so, how much?
Brainstorm Cell Therapeutics Inc(STU:GHD) does not pay dividend.

Press Release

Subject Date
No Press Release